SEEGNAL INC. ANNOUNCES FILING OF 2025 ANNUAL FILINGS AND THAT THE MCTO WILL NO LONGER BE IN EFFECT AS OF MAY 16, 2026

CALGARY, AB, May 17, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV:SEGN) (“Seegnal” or the “Company”) announces that the management cease trade order (the “MCTO”), issued by the Alberta Securities Commission on May 8, 2026, at the request of the Company, will no longer be in effect as of May 16, 2026.

On May 13, 2026, the Company filed its audited consolidated financial statements for the year ended December 31, 2025, together with the related management’s discussion and analysis and the Chief Executive Officer and the Chief Financial Officer certifications.

The MCTO applied only to the Chief Executive Officer and the Chief Financial Officer and did not affect the ability of the general investing public to trade in the Company’s securities.

The Company confirms that it is current with its continuous disclosure obligations and anticipates meeting its future filing requirements.

About Seegnal
Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal’s Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal’s SaaS technology exclusively integrates at the point-of-care, unique patient-specific data like genetics, results of lab tests, ECG, smoking, allergies, food, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Similarly, patients enjoy more tailored medication and improved safety, leading to better quality of life, due to the precision of alerts with up to 98% accuracy. Institutions reported a reduction in admissions, medication consumption, and ample time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in the State of Israel (where recently the Ministry of Health has adopted Seegnal’s patient-specific standard as the new standard in governmental hospitals), the UAE, the United Kingdom, the United States, and Poland. The platform is currently a “standard of care” system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients.

Schreibe Deinen Kommentar